It hasn't been the best quarter for Merck & Co., Inc. ( NYSE:MRK ) shareholders, since the share price has fallen ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

Exelixis and Merck & Co. have inked a deal to study Exelixis' investigational drug zanzalintinib in combination with a pair of Merck's cancer drugs. The companies in Wednesday said the agreement ...

(RTTNews) - Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development collaboration to evaluate the combination of Exelixis ...

The latest trading day saw Merck (MRK) settling at $111.53, representing a +1.68% change from its previous close.

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

Tis the season of snow and twinkling lights. The time for eating rich food and buying stuff. Lots of stuff. If the thought of ...